In MS and SLE patients, abzymes against myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG35–55, further designated as MOG) with proteolytic activity may attack MBP of the myelin-proteolipid sheath of axons. Here, MOG is linked to myeloid sarcoma.